Anemia and erythropoietin (rHuEPO) management program for optimal therapeutics and patient care

Clinical Research and Regulatory Affairs

Volumn 20, Issue 3, 2003, Pages 331-339

  Perkins, Linnea ^a   Hussein, Gamal ^b,c   Leung, Barries ^a  

^a Touro Infirmary   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AmerisourceBergen Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; COMPUTER PROGRAM; COST BENEFIT ANALYSIS; DRUG COST; DRUG UTILIZATION; HEALTH PROGRAM; INFORMATION PROCESSING; IRON DEFICIENCY; IRON THERAPY; LABORATORY TEST; PATIENT CARE; PRESCRIPTION; REVIEW;

EID: 0042472932     PISSN: 10601333     EISSN: None     Source Type: Journal    
DOI: 10.1081/CRP-120023846     Document Type: Review

References (13)

1. Massry SG, Glassock RJ. Kidney and endocrine system. In: Textbook of Nephrology. Vol. 1. Baltimore: Williams and Wilkins, 1995:191-197.
2. Jilani SM, Glaspy JA. Impact of epoetin alfa in chemotherapy-associated anemia. Seminars in Oncology 1998; 25(5):571-576.
3. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology 2001; 19(11):2875-2882.
4. Fernandez-Rodriguez AM, Guindeo MC, Molero-Labarta T, et al. Diagnosis of iron deficiency in chronic renal failure. American Journal of Kidney Disease 1999; 34(3):508-513.
5. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases 1995; 26(1):41-46.
6. Glaspy J, Cavill I. Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology 1999; 13(4):461-472.
7. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically III patient: a randomized, double-blind, placebo-controlled trial. Critical Care Medicine 1999; 27(11):2346-2350.
8. Heaney ML, Golde DW. Myelodysplasia. New England Journal of Medicine 1999; 340(21):1649-1660.
9. Epogen® Package Insert, Amgen, 2001.
10. Owen WF, Szczech L, Johnson C, et al. National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients. American Journal of Kidney Diseases 1999; 34(34, suppl 2):S5-S11.
11. MacDougall IC, Chandler G, Elston O, et al. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. American Journal of Kidney Diseases 1999; 34(4, suppl 2):S40-S46.
12. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney disease outcome quality initiative. American Journal of Kidney Diseases 2002; S1-246.
13. To LL, Stoner CP, Stolley SN, et al. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit. American Journal of Health-System Pharmacists 2001; 58(21):2061-2065.